What is the lead time for orders?

The average lead time is one month for both peak and off-season periods.

Mixed Feed Additives Liquid Citric Acid pH Regulator

Name: Mixed Feed Additives Liquid Citric Acid pH Regulator
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1946369882

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$2.95-3.25

1,000 Pieces

Sample price:US$5.00/piece.Request sample

Product profile

Customization

Available

Certification

ISO

Shape

Liquid, Powder

Model NO.

Oral Solution

Type

Vitamin

Function

Nutrition Enhancer

Transport Package

Carton

Specification

1L/bottle

Trademark

Moosun

Origin

China

HS Code

2309901000

Key features

Multi-Acid Composition: Contains formic, acetic, propionic, and citric acid for enhanced efficacy.

Improved Palatability: Sour flavor increases feed intake and promotes disease rehabilitation.

Versatile Application: Suitable for water supply system cleaning and animal drinking water purification.

Long Shelf Life: 3-year expiry date when stored in a dry, sealed, and light-protected place.

No Withdrawal Period: Safe for use with no required withdrawal period for animals.

ISO Certified Quality: Manufactured under ISO certification standards for quality assurance.

Custom OEM/ODM: OEM and ODM services available for customized nutrition enhancer solutions.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤11.82h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.